17-AAG- CAS 75747-14-7

17-AAG(cas# 75747-14-7), also known as  Tanespimycin or KOS-953, is a potent HSP90 inhibitor with IC50 of 5 nM, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. 17-AAG causes the degradation of HER2, Akt, and both mutant and wild-type AR and the retinoblastoma-dependent G1 growth arrest of prostate cancer cells. 17-AAG inhibits prostate cancer cell lines with IC50s ranged from 25-45 nM (LNCaP, 25 nM; LAPC-4, 40 nM; DU-145, 45 nM; and PC-3, 25 nM). Development of 17-AAG has been discontinued.

Catalog Number: I004806

CAS Number: 75747-14-7

PubChem Substance ID:355040753

Molecular Formula: C₃₁H₄₃N₃O₈

Molecular Weight:585.69

Purity: ≥95%

Inventory:In stock

Online inquiry

* For research use only. Not for human or veterinary use.


SynonymsTanespimycin;17-AAG; KOS-953; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate


Molecular Formula: C₃₁H₄₃N₃O₈
Molecular Weight585.69
SolubilityDMSO: ≥ 55 mg/mL
StorageStore at 4°C
Overview of Clinical ResearchOriginator: National Institutes of Health (USA)<br /> Developer: Kosan Biosciences<br /> Class: Antineoplastics; Benzoquinones; Cytostatic antibiotics; Macrocyclic lactams; Small molecules<br /> Mechanism of Action: HSP90 heat-shock protein inhibitors<br /> Orphan Drug Status: Yes – Multiple myeloma<br /> <p> New Molecular Entity: Yes</p> <p> Highest Development Phases: Discontinued Breast cancer;</p>
IC505 nM

Computed Descriptor